Adial Pharmaceuticals, Inc (NASDAQ:ADIL) Financings

Adial Pharmaceuticals, Inc

Financings

RaiseDate
Private placement of prefunded warrants
Update: about US$32M
Buyers: Coastlands Capital (led the financing); Boxer Capital Management; Stonepine Capital Management; AuGC BioFund; Kern Capital
Insiders: Insiders and management participated
Use of proceeds: Fund operations into 2028, including IND-enabling studies and initiation of the Phase 1 trial of AT177 in ulcerative colitis
Oct 28, 2026
Private placement of pre-funded warrants and common warrants
Tranche closed: US$32M raised · US$2.7489 a share · common warrants to purchase up to 11,780,948 shares of common stock, sold with… · Lucid Capital Markets +1
Dealers: Lucid Capital Markets (lead), TD Cowen
Buyers: Coastlands Capital (led the financing); Boxer Capital Management; Stonepine Capital Management; AuGC BioFund; Kern Capital (one of the lead investors)
Insiders: insiders and management participated
Use of proceeds: Advance its lead colon-targeted AhR program through key clinical milestones
Jun 16, 2026
Warrant exercise of series C-1 and Series E warrants exercised for common stock
Announced: about US$2.86M · US$0.31 a share · Warrants at US$0.31 for 24 months · A.G.P./Alliance Global Partners
Dealers: A.G.P./Alliance Global Partners
Buyers: existing healthcare-focused institutional investor (exercising the Existing Warrants for approximately $2.86 million)
Use of proceeds: Working capital and other general corporate purposes
Nov 26, 2025
Public offering of shares of common stock with Series D and Series E warrants
Announced: about US$3.6M · US$0.3251 a share · Warrants at US$0.35 · A.G.P./Alliance Global Partners
Dealers: A.G.P./Alliance Global Partners (lead)
Use of proceeds: Working capital and general corporate purposes
Jun 17, 2025
Warrant exercise of series B and Series C Warrants exercised for common stock
Announced: about US$2.75M · US$0.74 a share · Warrants at US$0.74 · A.G.P./Alliance Global Partners
Dealers: A.G.P./Alliance Global Partners
Use of proceeds: Working capital and other general corporate purposes
May 2, 2025

Read by 6ix AI from the company's releases